Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vasopressin in affective illness

P W Gold, F K Goodwin, V I Reus

    Lancet (London, England)
    |June 10, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Vasopressin, a peptide, influences complex behaviors and mood disorders like depression and mania. Its role in affective illness is being directly tested in humans.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Corrigendum to: Antidepressants worsen rapid-cycling course in bipolar disorder: A STEP-BD randomized clinical trial. J. Affect. Disord. (Jun. 10, 2015); http://dx.doi.org/10.1016/j.jad.2015.04.054.

    Journal of affective disorders·2017
    Same author

    Prospects for a scientific psychiatry.

    Acta neuropsychiatrica·2016
    Same author

    Bipolar disorder.

    Dialogues in clinical neuroscience·2011
    Same author

    The bipolar spectrum and the antidepressant view of the world.

    Journal of psychiatric practice·2005
    Same author

    What is to be done? Controversies in the diagnosis and treatment of manic-depressive illness.

    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2003
    Same author

    Topiramate treatment of bipolar spectrum disorders: a retrospective chart review.

    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists·2002
    Same journal

    Assisted dying and the silencing of medicine's next generation.

    Lancet (London, England)·2026
    Same journal

    Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

    Lancet (London, England)·2026
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    See all related articles

    Area of Science:

    • Neuroscience
    • Endocrinology
    • Psychiatry

    Background:

    • Vasopressin plays a role in behavior regulation.
    • Vasopressin is distributed throughout the central nervous system (C.N.S.) and cerebrospinal fluid (C.S.F.).
    • Vasopressin influences memory, pain, biological rhythms, sleep, and fluid balance.

    Purpose of the Study:

    • To investigate the role of vasopressin in complex behavioral syndromes.
    • To explore vasopressin's involvement in affective illnesses, including depression and mania.
    • To test the hypothesis that vasopressin is implicated in human behavioral disorders.

    Main Methods:

    • Animal studies on vasopressin deficiency and behavioral deficits.
    • Analysis of vasopressin distribution in the C.N.S. and C.S.F.

    Related Experiment Videos

  • Review of pharmacological and clinical data on vasopressin and mood alterations.

    • Main Results:

    • Vasopressin deficiency causes behavioral deficits reversed by vasopressin administration.
    • Vasopressin influences key processes implicated in affective illness.
    • Pharmacological agents affecting mood also alter vasopressin function.

    Conclusions:

    • Vasopressin is a candidate for involvement in complex behavioral syndromes.
    • Evidence suggests altered vasopressin function in depression and mania.
    • Direct testing of vasopressin's role in human behavioral disorders is now feasible.